GlassScriptPhysician profile
Samantha E Hill
NPI 1689875445
$6,639.43
in general payments reported to CMS, 2019-2025
30 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $213 · 2021: $464 · 2022: $760 · 2023: $1,213 · 2024: $937 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,638.80 |
| Education | $208.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,974.06 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $916.26 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Lilly USA, LLC | $669.62 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $468.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $463.23 | 2019-2025 | |
| Genentech USA, INC. | $240.27 | 2019-2020 | |
| Ucb, INC. | $218.13 | 2019-2025 | Bimzelx |
| Incyte Corporation | $216.61 | 2022-2024 | Opzelura |
| Amgen INC. | $216.60 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $161.38 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $140.94 | 2021-2024 | Dupixent |
| Pfizer INC. | $139.36 | 2019-2025 | |
| Leo Pharma INC. | $126.48 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $122.75 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $117.95 | 2019-2025 | Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $74.34 | 2024-2025 | Zoryve |
| Blueprint Medicines Corporation | $48.24 | 2024 | Ayvakit |
| Organon LLC | $44.86 | 2025 | |
| Celgene Corporation | $38.39 | 2019 | |
| Prugen, INC. Pharmaceuticals | $33.47 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $30.32 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.20 | 2022 | |
| Integra Lifesciences Corporation | $28.51 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Almirall LLC | $24.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.65 | 2023 | Xarelto |
| Ani Pharmaceuticals, INC. | $17.96 | 2025 | Purified Cortrophin Gel |
| Dermira, INC. | $16.54 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.56 | 2019 | |
| Mayne Pharma Commercial LLC | $13.80 | 2025 | |
| Merck Sharp & Dohme LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.